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Abstract
Raynaud’s phenomenon (RP) is an extremely unusual finding in early infancy. In the present report we describe a
one-month-old previously healthy male infant who presented with unilateral acrocyanosis. Although infantile
acrocyanosis is known to be a benign and self-resolving condition, it is generally bilateral and symmetric. The
unilateral nature of the acrocyanosis was an atypical finding in this infant. Consequently, he was closely monitored
to evaluate the progression of his acrocyanosis. Based on his benign clinical course and failure to demonstrate
other etiologies contributing to his acrocyanosis, he was diagnosed to have primary RP. Due to the rarity of RP in
children, we review the progress in understanding the pathophysiology, epidemiology and management of RP and
additionally discuss the differential diagnosis of unilateral and bilateral acrocyanosis in infants.
Background
Raynaud’s phenomenon (RP) was first described by
Maurice Raynaud in 1862 [1]. Classically, the initial
description of RP involved triphasic color changes in the
digits, with blanching (white) leading to cyanosis (blue)
followed by reactive hyperemia (red) [2,3]. However, it
has been realized that not every patient experiences all 3
phases of color change and the majority of patients pre-
sent with uniphasic color change involving an isolated
bluish discoloration of digits commonly known as acro-
cyanosis [4-6]. Unlike RP, acrocyanosis is a common
phenomenon in infants and young children [4-7]. Acro-
cyanosis is generally bilateral, symmetric and involves
hands and feet. Since infanti l ea c r o c y a n o s i si sab e n i g n
and self-resolving condition, it does not require medical
attention [7,8]. Rarely, acrocyanosis in infants can be
caused by RP and may require immediate medical atten-
tion to prevent complications of RP [9-13]. In this
report, we describe an infant who initially presented
with unilateral acrocyanosis and was diagnosed to have
primary RP based on his subsequent clinical course. In
view of the rarity of RP in infants and young children,
the literature about RP is reviewed with a specific focus
on the pediatric population. To help differentiate benign
acrocyanosis from acrocyanosis associated with other
serious conditions, the differential diagnosis of unilateral
and bilateral acrocyanosis in infants is also discussed.
Case report
A one-month-old healthy male infant was brought to his
pediatrician’s office for the evaluation of bluish to black-
ish discoloration of his left hand. His mother inciden-
tally noted this color change while she was changing his
diaper. She did not recall any trauma or insect bite. She
denied using naphthalene balls in the storage area for
the infant’s clothes. This history was helpful to exclude
methemoglobinemia as exposure to naphthalene balls
can cause infantile acrocyanosis [7]). He was breast-fed
and his mother was the primary care taker. The infant’s
birth history was unremarkable except for neonatal phy-
siological jaundice treated with phototherapy for 5 days.
His past history was noteworthy only for a history of
constipation. His family history was significant for
ischemic heart disease at a young age (< 55 years old) in
multiple members of his father’s family. His father died
at the age of 42 years due to a massive myocardial
infarction. His mother had a history of migraines. He
had three healthy siblings (three brothers, ages 11, 10
and 8 years).
Upon arrival at the outside hospital, he was an alert
and healthy infant in no acute distress. His physical
examination was normal including vital signs, growth
and development except for acrocyanosis of his left
hand with a clear demarcation at the wrist. His left
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sluggish capillary refill (~3 seconds). The peripheral and
central pulses were equal and regular bilaterally. He was
able to move all the extremities without any pain. The
elevated arm stress test was negative for worsening of
cyanosis or weakening of the radial pulse, thereby les-
sening the possibility of thoracic outlet syndrome. He
was referred to a tertiary pediatric facility where he was
admitted for further evaluation.
Evaluation during hospitalization
Upper extremity duplex ultrasound, MRI/MRA/MRV of
head, neck and left upper extremity were performed to
rule out anatomical disturbances in vascular supply.
Each test was negative. These results excluded several
conditions, including thromboembolism, thoracic outlet
syndrome contributing to compression of subclavian
vein, vascular anomalies, and the presence of a mass or
tumors in the region of cervical plexus including the
stellate ganglion. A transthoracic echocardiogram con-
firmed normal cardiac anatomy and did not demon-
strate any intracardiac mass, thrombus, or vegetation to
suggest an embolic source for a presumed thrombotic
event.
He underwent blood tests to detect infection and
other systemic causes of acrocyanosis such as methemo-
globinemia, polycythemia, antiphospholipid antibodies,
and other hypercoagulable conditions. The complete
blood count and comprehensive metabolic panel were
normal. The erythrocyte sedimentation rate (ESR) and
C-reactive protein (CRP) tests were also normal. His
newborn screen for inborn errors of metabolism and
hemoglobinopathies was negative. His coagulation tests
(PT and aPTT) were normal and antiphospholipid anti-
bodies and antinuclear antibody (ANA) assays were
negative. He also underwent testing for inherited throm-
bophilia such as factor V Leiden mutation, prothrombin
gene mutation, and methylene tetrahydrofolate reduc-
tase (MTHFR) mutation. Results were positive for
homozygosity for a MTHFR C677T mutation with nor-
mal homocysteine levels.
Due to the concerns about the transplacental transfer
of maternal antibodies contributing to development of
RP in this young infant, it was decided to evaluate his
mother for other medical conditions associated with RP
[14-16]. Her blood work up revealed no evidence for
systemic lupus erythematosus (antiphospholipid antibo-
dies, ANA, antidsDNA), scleroderma (antitopoisomerase
1 antibodies) or cryoglobulinemia (cryoglobulin levels).
Course during hospitalization and outpatient follow up
At admission, he was begun on low molecular weight
heparin (LMWH, dose: 1 mg/kg/dose, q 12 hourly) due
to the concerns of a thromboembolic event. He showed
gradual improvement in discoloration of his hands over
next 72-hours. Since there was no evidence of throm-
boembolism, his LMWH treatment was discontinued
after three days and it was decided to follow him closely
in an outpatient clinic without any further medical
intervention. Over the next few months he continued to
have 1-2 self-resolving episodes of acrocyanosis per
month, involving both hands along with bluishness of
tip of the nose, lips, ears and periumbilical area and
each lasting for a few minutes to an hour. They were
not associated with cold exposure but were felt to be
precipitated by abdominal colic due to constipation. At
9 months of age his initial tests for SLE, and other rheu-
matic diseases was repeated. This evaluation was
normal.
Based on his clinical course, he was diagnosed to have
“primary Raynaud’sp h e n o m e n o n ”. His treatment
included laxatives for constipation and close clinical
monitoring. Over the next one year, he continued to
have occasional episodes of acrocyanosis without any
medical consequences. At his last follow up (age 2
years), his growth and development was normal (length
and weight at 90th percentile).
Discussion
The infant described in this report presented with a uni-
lateral acrocyanosis at one month of age. He was diag-
nosed to have primary RP at 9 months. This diagnosis
was based on his clinical course and exclusion of other
causes of unilateral acrocyanosis including vascular
anomalies, thromboembolism and thoracic outlet syn-
drome. (Table 1) [7]. Even though acrocyanosis is very
common condition in newborn period, involvement of
only one hand was an atypical finding for infantile acro-
cyanosis. This finding provi d e dac l u et oc o n s i d e rt h e
possibility of RP in the differential diagnosis.
Over the last decade significant advances have been
made in understanding the pathophysiology of RP
[17-21]. Irrespective of the underlying etiology, RP is
manifested via vasospasm of the small muscular arteries
and arterioles of the digits [18]. Similar to benign acro-
cyanosis of infancy, RP is also triggered by exposure to
cold and emotional stress. It can be asymmetric and
may last longer than benign acrocyanosis. Based on the
available data, an over- activity of the sympathetic ner-
vous system along with an imbalance of vasodilator and
vasocontrictor substances may be the most likely etiol-
ogy for RP [18]. In patients with RP, digital cutaneous
neurons show a deficient release of a potent vasodilator,
the calcitonin-gene related peptide. This primary pathol-
ogy may be exaggerated by other factors as well, some
of which are influenced by cold or emotional triggers.
For example, in response to cold, various vasoconstrict-
ing substances such as catecholamines, endothelin-1,
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mediators could cause digital artery vasoconstriction
and the symptoms of RP. In some cases, this could trig-
ger a cascade of neutrophil and platelet activation,
which through the release of inflammatory agents such
as endothelin-1 and TNF-alpha, contribute to the
endothelial damage seen with more severe RP [21].
There is some suggestion that elevated levels of homo-
cysteine, a sulfur amino acid that is proposed as an
independent risk factor for atherosclerosis, may have an
association with RP [17,22,23]. RP appears to have a
strong familial component suggesting a genetic link,
though this link is yet to be clarified [20]. It is also
unclear if constipation can exaggerate the imbalance of
vasodilator and vascontrictor substances.
Raynaud’s phenomenon is traditionally classified as
‘primary’ (previously known as Raynaud’s disease) or
‘secondary’ [24]. Primary RP is diagnosed when it occurs
in the absence of associated diseases. In contrast, sec-
ondary RP is diagnosed in the presence of a well-defined
disease states such as SLE, polyarteritis nodosa (PAN) or
scleroderma (Table 2). [25-28] Primary RP is generally a
benign condition [13], but secondary RP can lead to sig-
nificant morbidity, including digital gangrene [29] and
may be life-threatening [9]. Of those patients with pri-
mary RP, ~13% of patients will eventually be diagnosed
to have secondary RP [11]. Although it is difficult to
predict which patients will be eventually diagnosed to
have secondary RP, children with secondary RP can
show changes in their nailfold capillaries. The direct
observation of the nailfold microvasculature with video-
capillaroscopy is useful for suspecting secondary RP ear-
lier during the clinical cours e[ 3 0 , 3 1 ] .G e n e r a l l y ,t h e
presence of giant capillaries, avascular fields and irregu-
lar architecture of nailfold capillaries is predictive of the
development of SLE, PAN, or scleroderma in patients
with RP [32]. According to Allen and Brown’s criteria of
minimum diagnosis, a negative antinuclear antibody
titer and negative findings on capillaroscopy are the
most reliable way to distinguish between primary and
secondary RP [33]. Since our patient’s clinical presenta-
tion (age, sex, clinical features) and blood workup was
consistent with primary RP, he was not evaluated for
capillary nailfold abnormalities.
Since RP is extremely rare in children, specifically in
infants, the knowledge about its epidemiology, clinical
spectrum and the natural evolution is quite limited
[9,11-13,29,34]. The first description of RP in children
appeared in 1967, almost 100 years after the initial
description of RP by Raynaud in 1862 [1]. This report
described a series of 6 children (ages, 2.5 to 5 years)
w i t hc l a s s i cR P[ 1 3 ] .S i n c e1 9 6 7 ,t h e r ea r eo n l ya
Table 1 Causes of acrocyanosis
Type of
acrocyanosis
Causes
Unilateral
acrocyanosis
Local trauma/digital injury
Local infection: Paronechia
Raynaud’s phenomenon
Thoracic outlet syndrome
Carpel Tunnel syndrome
Cervical tumors compressing neurovascular
bundle*
e.g. Neuroblastoma, stellate ganglion tumor
Thromboembolism of arteries of palmar arch
Frostbite
Reflex Sympathetic dystrophy
Bilateral
acrocyanosis**
Benign acrocyanosis of infancy
Frostbite
Pernio
Raynaud’s phenomenon
Reflex sympathetic dystrophy
Hypoxemia**
Congenital cyanotic heart disease**
Methemoglobinemia**
Purpura fulminans
Pheochromocytoma
*: Need to look for other signs of Horner’s syndrome on the ipsilateral side of
the face (ptosis, anhydrosis, miosis of pupil or unequal pupils, poor light reflex
and enopthalmos);**: Need close clinical evaluation for presence of central
cyanosis.
Table 2 Causes of Raynaud’s phenomenon
Category Disease conditions
Connective tissue/autoimmune
disorders
Scleroderma,
Dematomyositis,
Systemic lupus erythematosus,
Rheumatoid arthritis,
Sjogren’s syndrome
Antiphospholipid antibodies (APLA)
syndrome
Polyarteritis nodosa
Repetitive trauma Work involving tools with vibrations
Drugs Interferon-alpha,
Bleomycin
Ergotamine
Infections Helicobacter Pylori
Parvovirus B19
Metabolic Atherosclerosis
Cryoglobulinemia
Hyperhomocysteinemia
Chemical exposure Vinyl chloride exposure in plastic
industry
Smoking
Other Carpal-tunnel syndrome
CREST* syndrome
* CREST: calcinosis, Raynaud’s phenomenon, esophageal dysmotility,
sclerodactyly, and telangiectasia.
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eral, female children are more predisposed to develop-
ment of RP and the onset of RP generally occurs around
menarche implying the influence of ovarian hormones
in the pathogenesis of this entity [4,11,34]. Primary RP
is more common in children than secondary RP [11,34].
Earlier reports in children suggest the association of RP
with rheumatic diseases in children [34,36]. Similar to
adult literature, pediatric studies suggest that positive
ANA and abnormalities of nailfold capillaries may be
associated with secondary RP [34].
The largest cohort study inc h i l d r e np r o v i d e dm o r e
insight into the epidemiology of RP in children and
showed that RP is highly heterogeneous in children [11].
Although exposure to cold was the primary trigger in
the majority, (~70% of children) ~10% did not have any
known trigger. Primary RP followed a bimodal pattern
of age of onset affecting young infants and teenage
population. Half of these children experienced additional
symptoms such as pain, tingling, and numbness. Inter-
estingly, 11% (9/82) of children with primary RP were
lmisdiagnosed as “acrocyanosis” and 4 of them were
younger than 2 years of age. These 4 children uniformly
experienced monophasic or biphasic color change invol-
ving the whole hand, foot, or both under the influence
of cold or without an apparent cause. There are only
two case reports describing the RP in infants [9,29].
Both these infants presented at 5 months of age with
severe disease and required treatment with vasodilators.
A patient reported by Sayre initially presented with pre-
dominant involvement of right foot [29]. Her symptoms
were uniphasic and lasted for 72 hours prior to presen-
tation. At the age of 9 months, she showed involvement
of fingers as well. An infant described by Krigel et al.
[9], presented with acrocyanosis of toes for 3 days prior
to admission and showed classic RP with triphasic color
changes. The infant progressed to the development of
digital gangrene. This patient died at the age of 8
months due to vasomotor collapse. Her autopsy studies
revealed the diagnosis of PAN thus supporting second-
ary RP as the underlying cause of her acrocyanosis. Our
patient presented at an earlier age with mild symptoms
but his cyanosis lasted for almost 48-72 hours, similar
to both these cases. As transient APLAs have been
described in pregnant women [37], our initial work up
was focused on evaluating him and his mother for these
antibodies to rule out transplacental transfer of these
antibodies contributing to the clinical presentation.
Our patient was evaluated for genetic risk factors of
thrombosis due to the concerns about unilateral throm-
bosis at his presentation and the family history of young
age heart attacks [38]. He was homozygous for MTHFR
C677T mutation. MTHFR mutation can be associated
with hyperhomocysteinemia [39] and high homocysteine
levels are shown to be associated with decreased vasodi-
lation both in animal models [40] and in humans [41].
On the same note, patients with RP are shown to have
elevated homocysteine levels compared to normal con-
trols [42]. In our case the patient’s homocyteine levels
were normal, making this a less likely etiology for his
RP. However, whether MTHFR mutation in itself plays
a direct role in vascular instability is yet to be clarified.
Our patient was also evaluated for systemic causes of
central cyanosis such as methemoglobinemia and conge-
nital cyanotic heart disease. Generally this evaluation is
not required for children with unilateral acrocyanosis.
However, maternal anxiety and inability to provide a
long-term prognosis of this infant forced the medical
team to perform the extensive evaluation. Although dur-
ing two-years of follow up, there was no indication of
the other disorders which might be causal for the devel-
opment of RP, it is possible that in future his underlying
condition may become clinically evident.
Management of RP is generally supportive and relies
upon its accurate diagnosis. The mild forms of primary
RP can be controlled by non-pharmacologic approaches
such as avoidance of exposure to cold or emotional
stress. In moderate to severe cases, vasodilator therapy
including calcium channel blockers, either systemic or
topical, is required to relieve the vasospasm. Rarely
prostacycline infusions [43], antiplatelet agents [44,45]
and antithrombotic therapies [46] have been used with
variable success.
Surgery is reserved for extreme cases and generally
involves digital sympathectomy [47]. In the severe forms
of the disorder, intravenous infusion of prostacyclin as
well as endothelin-1 receptor antagonists and specific
inhibitors of phosphodiesterase-5 are emerging as the
treatment of choice [48,49]. Investigational agents for
the treatment of RP include selective alpha-2c adrener-
gic receptor blockers, inhibitors of protein tyrosine
kinase and Rho-kinase, as well as calcitonin gene-related
peptide. In patients with secondary RP, treatment of
underlying disease is critical to control the episodes of
RP.
Conclusion
This case report highlights that despite an improved
understanding of the pathophysiology of RP, the diagno-
s i so fp r i m a r yR Pi ni n f a n t si sc h a l l e n g i n ga n dI tc a n
take weeks to months to confirm the diagnosis. The rar-
ity of its occurrence in infants, the similarities in clinical
presentation between primary RP and benign acrocyano-
sis of infancy, and the absence of diagnostic tests con-
firming the diagnosis of primary RP contribute to delay
in the diagnosing of RP. Clinical clues that should alert
the clinician to suspect RP in infancy include the pre-
sence of atypical features such as a prolonged
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acrocyanosis. A high index of suspicion and close clini-
cal monitoring is required to ensure an accurate diagno-
sis and appropriate clinical management.
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